Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
- Resource Type
- Article
- Source
- In
International Immunopharmacology December 2023 125 Part B - Subject
- Language
- ISSN
- 1567-5769